Tag: late
Bluebird tanks as FDA’s LentiGlobin demands in sickle cell delay filing...
Shares of Bluebird Bio fell more than 20% in premarket trading Thursday after the gene therapy developer announced that the FDA is hitting the...
Amid Regeneron’s emergency use bid, former FDA chief says US ‘too...
Days removed from its star turn in President Donald Trump's COVID-19 treatment, Regeneron's antibody cocktail could be on the fast track to an emergency...
